LON:HIK - Hikma Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 1,869 +25.50 (+1.38 %) (As of 12/17/2018 06:36 AM ET)Previous CloseGBX 1,843.50Today's RangeGBX 1,833 - GBX 1,882.5052-Week RangeGBX 814.20 - GBX 2,346Volume159,303 shsAverage Volume822,138 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartDividendInsider TradesHeadlines Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including anti-infective, anaesthetic, central nervous system (CNS), oncology, and pain management, as well as controlled substances and cardiovascular products. The Generics segment develops and sells approximately 100 oral and other non-injectable generic products for oncology and pain management, as well as respiratory, nasal spray, suspension, liquid solution, and high-containment areas. The Branded segment develops, manufactures, and markets branded generics and in-licensed products, such as anti-infective products, as well as chronic therapeutic categories comprising cardiovascular, diabetes, CNS, and oncology products. The company also manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom. Receive HIK News and Ratings via Email Sign-up to receive the latest news and ratings for HIK and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolLON:HIK Previous Symbol CUSIPN/A Webwww.hikma.com Phone+44-20-73992760 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees8,500 Outstanding SharesN/AMarket Cap£0.00 OptionableNot Optionable Hikma Pharmaceuticals (LON:HIK) Frequently Asked Questions What is Hikma Pharmaceuticals' stock symbol? Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK." How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals? Hikma Pharmaceuticals announced a dividend on Wednesday, August 15th. Shareholders of record on Thursday, August 23rd will be given a dividend of GBX 0.12 per share on Friday, September 21st. This represents a dividend yield of 0.53%. The ex-dividend date is Thursday, August 23rd. The official announcement can be accessed at this link. View Hikma Pharmaceuticals' Dividend History. What price target have analysts set for HIK? 7 analysts have issued twelve-month price objectives for Hikma Pharmaceuticals' stock. Their forecasts range from GBX 1,050 to GBX 2,250. On average, they expect Hikma Pharmaceuticals' stock price to reach GBX 1,815.71 in the next twelve months. This suggests that the stock has a possible downside of 2.9%. View Analyst Price Targets for Hikma Pharmaceuticals. What is the consensus analysts' recommendation for Hikma Pharmaceuticals? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 5 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Hikma Pharmaceuticals. Has Hikma Pharmaceuticals been receiving favorable news coverage? News coverage about HIK stock has been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Hikma Pharmaceuticals earned a news impact score of 1.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. Who are some of Hikma Pharmaceuticals' key competitors? Some companies that are related to Hikma Pharmaceuticals include Acerus Pharmaceuticals (ASP), Aequus Pharmaceuticals (AQS), Amryt Pharma (AMYT), Aphria (APH), Aurora Cannabis (ACB), Bausch Health Companies (BHC), Benchmark (BMK), Biosyent (RX), Cannabis Science (CBIS), Canopy Growth (WEED), Charlotte's Web (CWBHF), Choom (CHOOF), Cipher Pharmaceuticals (CPHRF), Cipher Pharmaceuticals (CPH) and Cosmos (COSM). Who are Hikma Pharmaceuticals' key executives? Hikma Pharmaceuticals' management team includes the folowing people: Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 61)Mr. Mazen Samih Taleb Darwazeh, Exec. Vice Chairman, CEO and Pres of MENA & Emerging Markets (Age 60)Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 49)Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 46)Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D How do I buy shares of Hikma Pharmaceuticals? Shares of HIK and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Hikma Pharmaceuticals' stock price today? One share of HIK stock can currently be purchased for approximately GBX 1,869. What is Hikma Pharmaceuticals' official website? The official website for Hikma Pharmaceuticals is http://www.hikma.com/. How can I contact Hikma Pharmaceuticals? Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The company can be reached via phone at +44-20-73992760. MarketBeat Community Rating for Hikma Pharmaceuticals (LON HIK)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 549 (Vote Outperform)Underperform Votes: 380 (Vote Underperform)Total Votes: 929MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HIK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HIK will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/17/2018 by MarketBeat.com StaffFeatured Article: What does the Dow Jones Industrial Average (DJIA) measure?